The Department of the Army Medical Command awarded a $475,457 Project Grant to the Institute of Cancer Research: Royal Cancer Hospital in the United Kingdom. The grant is part of the Military Medical Research and Development program (CFDA 12.420) and will fund research characterizing biomarkers of growth and progression in small renal masses from September 30, 2022 to September 29, 2025. Through this award, the grantee will investigate medical solutions for the battlefield by transforming healthcare for service members and the public. Specifically, the research aims to develop biomarkers for early detection and targeted treatment of kidney cancer, with the goal of improving outcomes for those with small renal masses.